Healthcare entity
Of the tracked stories, 3 of 8 also mention Kenvue, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.8 for the same window. Across a 159-day span, the pace is roughly 0.4 stories per week.
Last mentioned: 1d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 8 also mention Kenvue, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.8 for the same window. Across a 159-day span, the pace is roughly 0.4 stories per week. Against the same-window beat baseline of 26% negative, this entity's 25% share is less negative. market-trends accounts for 4 of the 8 tracked stories, while 2 other categories carry the remainder. At 5.9, the average consequence score sits below the same-window beat average of 6.1. This profile follows 8 Healthcare stories mentioning Johnson & Johnson across the period from February 25, 2026 to August 2, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 909 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johnson & Johnson. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Milestone
Protagonist receives $231M milestone payment for icotrokinra progress.
Colorado’s $12M opioid grant round, awarded to 27 organizations, will bolster youth treatment, prison re-entry support, and a rural behavioral health workforce—key gaps in the state’s healthcare delivery system. The highly competitive process drew 287 applications, highlighting the severe need for prevention infrastructure.
The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Source: The Motley Fool · fool.com
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Source: themarketsdaily.com · tickerreport.com
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Source: finance.yahoo.com · insidermonkey.com
A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
Source: finanznachrichten.de · prnewswire.com
A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.
Source: nbclosangeles.com · nbcsandiego.com
Johnson & Johnson is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
